Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2
Science Advances · 2025
DOI: 10.1126/sciadv.ady6760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Rebecca A Gibson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27705, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Dependovirus, Liver, Genetic Vectors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIGMS NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Glycogen storage disease (GSD) type IX γ2 is a rare inborn error of metabolism where a defect in glycogenolysis leads to the inability to break down glycogen in the liver. Patients with GSD IX γ2 develop hypoglycemia and advanced liver disease, placing them at risk for liver transplantation. This study evaluates the efficacy of liver-directed AAV gene therapy in a murine model of GSD IX γ2. Phkg2 −/− mice underwent treatment with AAV gene therapy (AAV9-LSP- mPhkg2 , 5 × 10 12 vg/kg, intravenous delivery) at ages 3 or 6 months and were treated for either 2 weeks, 3 months, or 12 months. Results demonstrated that AAV gene therapy reduced GSD IX γ2 disease burden across all primary end points. AAV gene therapy also persisted across the mouse lifespan and reduced preexisting liver fibrosis. This work provides preclinical data supporting AAV gene therapy as a definitive treatment for GSD IX γ2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27705, USA.
- Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27705, USA.
- Department of Pathology, Duke University Medical Center, Durham, NC 27705, USA.
- Department of Surgery, Duke University Medical Center, Durham, NC 27705, USA.
ORCID-Profile: Rebecca A Gibson, William R Jeck, Rebecca L Koch, Neha Jumani, Su Jin Choi, Deeksha Bali, Sarah P Young, Aravind Asokan, Jeong-A Lim, Priya S Kishnani
Förderung
- NICHD NIH HHS
- NIGMS NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Kriya Therapeutics
Zitieren
APA
Gibson, R. A., Jeck, W. R., Koch, R. L., Jumani, N., Choi, S. J., Bali, D., Young, S. P., Asokan, A., Lim, J. A., & Kishnani, P. S. (2025). Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2. Science Advances. https://doi.org/10.1126/sciadv.ady6760
Vancouver
Gibson RA, Jeck WR, Koch RL, Jumani N, Choi SJ, Bali D, et al. Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2. Science Advances. 2025. doi:10.1126/sciadv.ady6760
BibTeX
@article{Gibson2025,
author = {Gibson, Rebecca A and Jeck, William R and Koch, Rebecca L and Jumani, Neha and Choi, Su Jin and Bali, Deeksha and Young, Sarah P and Asokan, Aravind and Lim, Jeong-A and Kishnani, Priya S},
title = {Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.ady6760}
}
EUVIMED